

CLAIMS

What is claimed is:

1. A synthetic peptide comprising at least about 95% sequence identity to an amino acid sequence selected from the group of SEQ ID NO: 6-13.
2. The synthetic peptide of claim 1 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 6-13.
3. The synthetic peptide of claim 1 comprising at least about 95% sequence identity to amino acid sequence selected from the group consisting of SEQ ID NOs: 7-11.
4. The synthetic peptide of claim 1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 7-11.
5. The synthetic peptide of claim 1 consisting of an amino acid sequence comprising at least about 95% sequence identity to SEQ ID NO: 6.
6. The synthetic peptide of claim 1 consisting of an amino acid sequence comprising at least about 95% sequence identity to SEQ ID NO: 7.
7. The synthetic peptide of claim 1 consisting of an amino acid sequence comprising at least about 95% sequence identity to SEQ ID NO: 8.
8. The synthetic peptide of claim 1 consisting of an amino acid sequence comprising at least about 95% sequence identity to SEQ ID NO: 9.
9. The synthetic peptide of claim 1 consisting of an amino acid sequence comprising at least about 95% sequence identity to SEQ ID NO: 10.
10. The synthetic peptide of claim 1 consisting of an amino acid sequence comprising at least about 95% sequence identity to SEQ ID NO: 11.
11. The synthetic peptide of claim 1 consisting of an amino acid sequence comprising at least about 95% sequence identity to SEQ ID NO: 12.
12. The synthetic peptide of claim 1 consisting of an amino acid sequence comprising at least about 95% sequence identity to SEQ ID NO: 13.

13. A pharmaceutical composition comprising a therapeutically effective amount of the synthetic peptide of any of claims 1-12 and at least one pharmaceutically acceptable carrier, diluent, or excipient.

14. Use of the pharmaceutical composition of claim 13 in the manufacture of a medicament
~~for A method of regulating the complement system comprising administering the~~
~~pharmaceutical composition of claim 13 to a subject in need thereof.~~

15. Use of the pharmaceutical composition of claim 13 in the manufacture of a medicament
~~for A method of inhibiting myeloperoxidase activity comprising administering the~~
~~pharmaceutical composition of claim 13 to a subject in need thereof.~~

16. Use of the pharmaceutical composition of claim 13 in the manufacture of a medicament
~~for A method of inhibiting oxidant activity comprising administering the pharmaceutical~~
~~composition of claim 13 to a subject in need thereof.~~

17. Use of the pharmaceutical composition of claim 13 in the manufacture of a medicament
~~for A method of inhibiting PD-1 binding to PD-L1 comprising administering the~~
~~pharmaceutical composition of claim 13 to a subject in need thereof.~~

18. Use of the pharmaceutical composition of claim 13 in the manufacture of a medicament
~~for A method of inhibiting T cell exhaustion comprising administering the pharmaceutical~~
~~composition of claim 13 to a subject in need thereof.~~

19. Use of the pharmaceutical composition of claim 13 in the manufacture of a medicament
~~for A method of inhibiting angiogenesis comprising administering the pharmaceutical~~
~~composition of claim 13 to a subject in need thereof.~~

20. The pharmaceutical composition of claim 13 for use in therapy.